Dr. Harlan Robins co-founded Adaptive Biotechnologies in September 2009 and has served as its Chief Scientific Officer (or Head of Innovation) since incorporation, leading the science behind the company's immune medicine platform and its TCR-antigen mapping work. He previously held roles in the Computational Biology Program at Fred Hutchinson Cancer Research Center, including Assistant Faculty Member (2006-2011), Associate (2011-2016) and Full Member and Head of the program (2016-2019). He is the brother of Chief Executive Officer Chad Robins. Dr. Robins holds a BS in Physics from Harvard University and an MS and PhD in Physics from the University of California, Berkeley, and completed postdoctoral appointments at the Weizmann Institute of Science and the Institute for Advanced Study at Princeton University.